Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)

Publication | Closed Access

DOI

238

Citations

References

2023

Year

Keith S. Kaye, Andrew F. Shorr, Richard G. Wunderink, Bin Du, Gabrielle Poirier, Khurram Rana, Alita A. Miller, Drew Lewis, John P. O’Donnell, Lan Chen,

The Lancet Infectious Diseases

Antimicrobial SusceptibilityAntimicrobial StewardshipAntibioticsMedicineSulbactam–durlobactam Versus ColistinAntibacterial AgentAntimicrobial TherapyAntimicrobial PharmacokineticsInfection ControlAntimicrobial PharmacodynamicsBacterial PathogensClinical MicrobiologyAntimicrobial ResistancePhase 3Serious Infections